Abstracts tagged "gout"

Abstract Number: 2351 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Alexandra Steinberg, Yun-Jung Choi, Robert Martin, Charles McWherter and Pol Boudes, Cymabay Therapeutics, Newark, CA
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) for the treatment of gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular…
Abstract Number: 223 • 2015 ACR/ARHP Annual Meeting
Increased Platelet Reactivity in Gout: A Potential Mechanism for Adverse Cardiovascular Events
Richard Conway¹, Claire-Louise Murphy², Anne Madigan², Patricia Kavanagh², Liz Geraghty², Laura Helbert², Kelly Stephens³, John J. Carey⁴, Eimear Dunne⁵, Dermot Kenny⁵ and Geraldine M. McCarthy⁶, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 2, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Mater Misericordiae University Hospital, Clinical Research Center, Dublin, Ireland, ⁴Rheumatology, Galway University Hospitals, Galway, Ireland, ⁵Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁶University College Dublin, Dublin, Ireland
Background/Purpose: Patients with inflammatory arthritis, including gout, have an increased risk of cardiovascular events and mortality. Increased platelet reactivity is a risk marker for cardiovascular…
Abstract Number: 2099 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Clinically-Defined Gout Identifies Multiple Risk Loci: A Clue for Future Companion Diagnostics of Gout
Hirotaka Matsuo¹, Ken Yamamoto², Hirofumi Nakaoka³, Akiyoshi Nakayama¹, Masayuki Sakiyama¹, Atsushi Takahashi^4,5, Takahiro Nakamura⁶, Yusuke Kawamura¹, Nobuyuki Hamajima⁷, Ituro Inoue⁸, Michiaki Kubo⁴, Kimiyoshi Ichida⁹, Hiroshi Ooyama¹⁰, Toru Shimizu¹¹ and Nariyoshi Shinomiya¹, ¹Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ²Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan, ³Division of Human Genetics, Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, ⁴Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁵Research Center, National Cerebral and Cardiovascular Center, Suita, Japan, ⁶National Defense Medical College, Laboratory for Mathematics, Tokorozawa, Japan, ⁷Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁸Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, ⁹Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan, ¹⁰Ryougoku East Gate Clinic, Tokyo, Japan, ¹¹Midorigaoka Hospital, Takatsuki, Japan
Background/Purpose: Gout, caused by hyperuricaemia, is a multifactorial disease. Recently, genome-wide association studies (GWASs) of gout have been reported; however, they included self-reported gout cases.…
Abstract Number: 2352 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety in Patients with Tophaceous Gout Receiving Lesinurad and Febuxostat Combination Therapy: Interim Analysis of an Extension Study
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Scott Adler⁶, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁵, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: In the randomized, double-blind, placebo-controlled, Phase III CRYSTAL trial, more patients taking lesinurad 200 mg (LESU200) or 400 mg (LESU400), in combination with febuxostat…
Abstract Number: 226 • 2015 ACR/ARHP Annual Meeting
Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both
Daisy Bang¹, Jinfeng Xu², Robert T. Keenan³, Virginia Pike¹, Aaron Lehmann¹, Craig T. Tenner⁴, Daria Crittenden¹, Michael H. Pillinger¹ and Svetlana Krasnokutsky¹, ¹Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ²Biostatistics, New York University School of Medicine, New York, NY, ³Rheumatology, Duke University, Durham, NC, ⁴Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Osteoarthritis (OA) and gout are each associated with increased cardiovascular disease (CVD), but their relative impacts on CV risk are not known. We compared…
Abstract Number: 2108 • 2015 ACR/ARHP Annual Meeting
A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout
Ted R. Mikuls¹, T C Cheetham², Nazia Rashid², Gerald D. Levy³, Artak Kerimian⁴, KJ Low², Brian Coburn⁵, David T. Redden⁶, S. Louis Bridges Jr.⁷, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA, ³Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Ambulatory Care Pharmacy, Kaiser Permanente Southern California, Downey, CA, ⁵Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout is a common form of inflammatory arthritis, often treated with allopurinol as a first-line urate lowering therapy. We have designed a large…
Abstract Number: 2353 • 2015 ACR/ARHP Annual Meeting
Lesinurad and Febuxostat Combination Therapy: Analysis of Treatment Based on Patient Baseline Renal Function
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Scott Adler⁶, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁵, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: A randomized, double-blind, placebo-controlled, Phase III clinical trial showed that lesinurad, a selective uric acid reabsorption inhibitor (SURI), in combination with febuxostat 80 mg…
Abstract Number: 227 • 2015 ACR/ARHP Annual Meeting
Impact of Gout on the Risk of Atrial Fibrillation
Chang-Fu Kuo¹, Matthew J. Grainge², Weiya Zhang³ and Michael Doherty⁴, ¹Division of Rheumatoplogy, Allergy and Immunology, Chang Gung Memorial Hospital, Tayuan, Taiwan, ²Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom, ³Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ⁴Academic Rheumatology, City Hospital, Nottingham, United Kingdom
Background/Purpose: To examine the risk of atrial fibrillation (AF) at the time of first diagnosis of gout compared to matched controls and to follow incident…
Abstract Number: 2112 • 2015 ACR/ARHP Annual Meeting
Analysis of Gout Subjects Receiving Lesinurad and Allopurinol Combination Therapy By Baseline Renal Function
Kenneth G. Saag¹, Thomas Bardin², Alexander So^3,4, Puja Khanna⁵, Chris Storgard⁶, Scott Baumgartner⁷, Maple Fung⁷, Nihar Bhakta⁷, Scott Adler⁸, Jeff Kopicko⁷ and Michael A. Becker⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Lariboisière Hospital, Paris, France, ³Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ⁴CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁵Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Ardea Biosciences, Inc., San Diego, CA, ⁸AstraZeneca Pharmaceuticals, Wilmington, DE, ⁹University of Chicago, Chicago, IL
Background/Purpose: Two randomized, double-blind, placebo-controlled Phase III clinical trials showed that lesinurad (200 or 400 mg) when added to allopurinol (200-900 mg) significantly increased the…
Abstract Number: 2354 • 2015 ACR/ARHP Annual Meeting
The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors
Robert Terkeltaub¹, Fernando Perez-Ruiz^2,3,4, Jeff Kopicko⁵, Maple Fung⁵, Scott Adler⁶, Chris Storgard⁷, Scott Baumgartner⁵ and Nicola Dalbeth⁸, ¹Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ²Rheumatology Division, Hospital Universitario Cruces, Barakaldo, Spain, ³BioCruces Health Research Institute, Baracaldo, Spain, ⁴Servicio de Reumatologia, Hospital De Cruces, Baracaldo, Spain, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Previous studies have shown that long-term urate-lowering therapy (ULT) is required for improvements in gout flare frequency and tophi reduction, and that lower serum…
Abstract Number: 231 • 2015 ACR/ARHP Annual Meeting
Uric Acid Levels Predict Mortality in Women
Jenni E Kauppi¹, Tuomo Nieminen^2,3, Mika Kähönen^4,5, Anne Kerola⁶, Antti Jula⁷, Jaana Leiviskä⁸ and Markku J. Kauppi^9,10, ¹School of medicine, University of Tampere, Tampere, Finland, ²Department of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ³Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, ⁴Department of Clinical physiology, School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Clinical Physiology, Medical Imaging Centre, Pirkanmaa Hospital District, Tampere, Finland, ⁶Faculty of Medicine, University of Helsinki, Helsinki, Finland, ⁷Department of Health, National Institute for Health and Welfare, Turku, Finland, ⁸Department of Health, National Institute for Health and Welfare, Helsinki, Finland, ⁹School of Medicine, University of Tampere, Tampere, Finland, ¹⁰Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland
Background/Purpose: Hyperuricemia induces chronic inflammation and is associated with many diseases such as metabolic syndrome, high blood pressure, chronic kidney disease and cardiovascular diseases. The…
Abstract Number: 2113 • 2015 ACR/ARHP Annual Meeting
Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁶, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: Lesinurad (LESU; RDEA594) is a selective uric acid reabsorption inhibitor (SURI) being investigated for the treatment of gout in combination with a xanthine oxidase…
Abstract Number: 3165 • 2015 ACR/ARHP Annual Meeting
Do Omega-3 Fatty Acids Reduce Risk of Recurrent Gout Attacks?
MaryAnn Zhang¹, Yuqing Zhang², Robert Terkeltaub³, Clara Chen⁴ and Tuhina Neogi², ¹Internal Medicine, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴Boston University School of Public Health, Boston, MA
Background/Purpose: Current guidelines for gout management, based in part on epidemiologic data for development of incident gout, recommend limiting intake of high-purine fish. However,…
Abstract Number: 233 • 2015 ACR/ARHP Annual Meeting
Gout Does Not Decrease the Risk of Parkinson’s Disease: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Charat Thongprayoon² and Narat Srivali³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Internal medicine, Bassett medical center, Cooperstown, NY, ³Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
Gout Does Not Decrease the Risk of Parkinson's Disease: A Systematic Review and Meta-analysisBackground/Purpose: Uric acid is a potent anti-oxidant and hyperuricemia is well-linked to…
Abstract Number: 2228 • 2015 ACR/ARHP Annual Meeting
Brief Educational Intervention Improves Gout Patients’ Understanding of Their Disease
Slavica Bobic¹, Mark Tratenberg¹, Julia Ash¹, Amy Wasserman² and Kirk Sperber¹, ¹Rheumatology, New York Medical College, Valhalla, NY, ²New York Medical College, Valhalla, NY
Background/Purpose: To assess gout patients’ baseline knowledge of their disease and to measure knowledge improvement after brief educational session. Methods: In this study, 13 patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].